Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita

Journal of Pathology

Volumn 225, Issue 3, 2011, Pages 401-413

  Kopecki, Zlatko ^a,b   Arkell, Ruth M ^c   Strudwick, Xanthe L ^a   Hirose, Misa ^d   Ludwig, Ralf J ^d   Kern, Johannes S ^e,f   Bruckner Tuderman, Leena ^e,f   Zillikens, Detlef ^d   Murrell, Dedee F ^g   Cowin, Allison J ^a,b,h  

^a CHILD HEALTH RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

epidermolysis bullosa; Flightless; Flii; TGF ; type VII collagen; wound healing

Indexed keywords

ACTIN; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 7; INTEGRIN; PROTEIN FLIGHTLESS 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; BLISTER; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMOLYSIS BULLOSA ACQUISITA; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WOUND HEALING;

ANIMALS; AUTOIMMUNE DISEASES; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE VII; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SKIN; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 80054719489     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2973     Document Type: Article

References (52)

1. Ferrari S, Pellegrini G, Mavilio F, et al., Gene therapy approaches for epidermolysis bullosa. Clin Dermatol 2005; 23: 430-436. (Pubitemid 40968117)
2. Fine JD,. Inherited epidermolysis bullosa: past, present, and future. Ann N Y Acad Sci 2010; 1194: 213-222.
3. Uitto J,. Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies. Acta Derm Venereol 2009; 89: 228-235.
4. Aumailley M, Has C, Tunggal L, et al., Molecular basis of inherited skin-blistering disorders, and therapeutic implications. Expert Rev Mol Med 2006; 8: 1-21. (Pubitemid 44605421)
5. Uitto J, McGrath JA, Rodeck U, et al., Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol 2010; 130: 1778-1784.
6. Kopecki Z, Murrell DF, Cowin A,. Raising the roof on epidermolysis bullosa (EB): a focus on new therapies. Wound Practice Res 2009; 17: 76-82.
7. Fine JD, Eady RA, Bauer EA, et al., The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58: 931-950.
8. Uitto J, Pulkkinen L,. The genodermatoses: candidate diseases for gene therapy. Hum Gene Ther 2000; 11: 2267-2275.
9. Lehman JS, Camilleri MJ, Gibson LE,. Epidermolysis bullosa acquisita: concise review and practical considerations. Int J Dermatol 2009; 48: 227-235; quiz 35-36.
10. Remington J, Chen M, Burnett J, et al., Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Curr Dir Autoimmun 2008; 10: 195-205.
11. Woodley DT, Remington J, Chen M,. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Clin Rev Allergy Immunol 2007; 33: 78-84.
12. Langan SM, Williams HC,. A systemic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin Exp Dermatol 2008; 34: 20-25.
13. Petrova A, Ilic D, McGrath JA,. Stem cell therapies for recessive dystrophic epidermolysis bullosa. Br J Dermatol 2010; 163: 1149-1156.
14. Uitto J,. Epidermolysis bullosa: prospects for cell-based therapies. J Invest Dermatol 2008; 128: 2140-2142.
15. Kirtschig G, Murrell DF, Wojanarowska F, et al., Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita (The Cochrane review). Cochrane Database Sys Rev 2003. CD004056.
16. Kopecki Z, Arkell R, Powell BC, et al., Flightless I regulates hemidesmosome formation and integrin-mediated cellular adhesion and migration during wound repair. J Invest Dermatol 2009; 129: 2031-2045.
17. Campbell HD, Fountain S, Young IG, et al., Genomic structure, evolution, and expression of human FLII, a gelsolin and leucine-rich-repeat family member: overlap with LLGL. Genomics 1997; 42: 46-54. (Pubitemid 27215125)
18. Archer SK, Claudianos C, Campbell HD,. Evolution of the gelsolin family of actin-binding proteins as novel transcriptional coactivators. Bioessays 2005; 27: 388-396. (Pubitemid 40592595)
19. Campbell HD, Schimansky T, Claudianos C, et al., The Drosophila melanogaster flightless-I gene involved in gastrulation and muscle degeneration encodes gelsolin-like and leucine-rich repeat domains and is conserved in Caenorhabditis elegans and humans. Proc Natl Acad Sci U S A 1993; 90: 11386-11390. (Pubitemid 23354434)
20. Kopecki Z, Cowin AJ,. Flightless I: an actin-remodelling protein and an important negative regulator of wound repair. Int J Biochem Cell Biol 2008; 40: 1415-1419. (Pubitemid 351626699)
21. Adams DH, Strudwick XL, Kopecki Z, et al., Gender specific effects on the actin-remodelling protein Flightless I and TGF-beta1 contribute to impaired wound healing in aged skin. Int J Biochem Cell Biol 2008; 40: 1555-1569.
22. Cowin A, Adams D, Strudwick X, et al., Flightless I deficiency enhances wound repair by increasing cell migration and proliferation. J Pathol 2007; 211: 572-581. (Pubitemid 46502434)
23. Davy DA, Campbell HD, Fountain S, et al., The flightless I protein colocalizes with actin- and microtubule-based structures in motile Swiss 3T3 fibroblasts: evidence for the involvement of PI 3-kinase and Ras-related small GTPases. J Cell Sci 2001; 114: 549-562. (Pubitemid 32186112)
24. Archer SK, Behm CA, Claudianos C, et al., The flightless I protein and the gelsolin family in nuclear hormone receptor-mediated signalling. Biochem Soc Trans 2004; 32: 940-942. (Pubitemid 39655510)
25. Lee YH, Stallcup MR,. Interplay of Fli-I and FLAP1 for regulation of beta-catenin dependent transcription. Nucleic Acids Res 2006; 34: 5052-5059. (Pubitemid 44742472)
26. Dai P, Jeong SY, Yu Y, et al., Modulation of TLR signaling by multiple MyD88-interacting partners including leucine-rich repeat Fli-I-interacting proteins. J Immunol 2009; 182: 3450-3460.
27. Li J, Yin HL, Yuan J,. Flightless-I regulates proinflammatory caspases by selectively modulating intracellular localization and caspase activity. J Cell Biol 2008; 181: 321-333. (Pubitemid 351574556)
28. Wang T, Chuang TH, Ronni T, et al., Flightless I homolog negatively modulates the TLR pathway. J Immunol 2006; 176: 1355-1362. (Pubitemid 43134277)
29. Campbell HD, Fountain S, McLennan IS, et al., Fliih, a gelsolin-related cytoskeletal regulator essential for early mammalian embryonic development. Mol Cell Biol 2002; 22: 3518-3526. (Pubitemid 34453990)
30. Adams DH, Ruzehaji N, Strudwick XL, et al., Attenuation of Flightless I, an actin-remodelling protein, improves burn injury repair via modulation of transforming growth factor (TGF)-beta1 and TGF-beta3. Br J Dermatol 2009; 161: 326-336.
31. Sitaru C, Mihai S, Otto C, et al., Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115: 870-878. (Pubitemid 40489391)
32. Fritsch A, Loeckermann S, Kern JS, et al., A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 2008; 118: 1669-1679. (Pubitemid 351632371)
33. Geary SM, Cowin AJ, Copeland B, et al., The role of the tetraspanin CD151 in primary keratinocyte and fibroblast functions: implications for wound healing. Exp Cell Res 2008; 314: 2165-2175.
34. Berrier AL, Yamada KM,. Cell-matrix adhesion. J Cell Physiol 2007; 213: 565-573. (Pubitemid 350058247)
35. Cowin AJ, Adams D, Geary SM, et al., Wound healing is defective in mice lacking tetraspanin CD151. J Invest Dermatol 2006; 126: 680-689. (Pubitemid 43255660)
36. Fine JD, Johnson LB, Weiner M, et al., Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986-2002. J Hand Surg Br 2005; 30: 14-22. (Pubitemid 40058049)
37. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, et al., p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci 2006; 47: 1500-1509. (Pubitemid 46780758)
38. Remington J, Wang X, Hou Y, et al., Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009; 17: 26-33.
39. Kligys K, Jones JC,. Flii control: balancing migration and adhesion. J Invest Dermatol 2009; 129: 1856-1858.
40. Chung HJ, Uitto J,. Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28: 93-105.
41. Konig A, Bruckner-Tuderman L,. Transforming growth factor-beta promotes deposition of collagen VII in a modified organotypic skin model. Lab Invest 1994; 70: 203-209.
42. Naso M, Uitto J, Klement JF,. Transcriptional control of the mouse Col7a1 gene in keratinocytes: basal and transforming growth factor-beta regulated expression. J Invest Dermatol 2003; 121: 1469-1478. (Pubitemid 38005501)
43. Ryynanen J, Sollberg S, Olsen DR, et al., Transforming growth factor-beta up-regulates type VII collagen gene expression in normal and transformed epidermal keratinocytes in culture. Biochem Biophys Res Commun 1991; 180: 673-680.
44. Vindevoghel L, Kon A, Lechleider RJ, et al., Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta. J Biol Chem 1998; 273: 13053-13057. (Pubitemid 28246870)
45. Fritsch A, Kern JS, Loeckermann S, et al., Conditional collagen VII inactivation allows analysis of anchoring fibril stability and function in vivo and reveals a major role of fibroblasts in collagen VII expression. J Invest Dermatol 2009; 129 (Suppl 1): S81.
46. Bruckner-Tuderman L, McGrath JA, Robinson EC, et al., Animal models of epidermolysis bullosa: update 2010. J Invest Dermatol 2010; 130: 1485-1488.
47. Wong T, Gammon L, Liu L, et al., Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128: 2179-2189.
48. Kern JS, Loeckermann S, Fritsch A, et al., Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther 2009; 17: 1605-1615.
49. Woodley DT, Krueger GG, Jorgensen CM, et al., Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003; 121: 1021-1028. (Pubitemid 37430968)
50. Konig A, Lauharanta J, Bruckner-Tuderman L,. Keratinocytes and fibroblasts from a patient with mutilating dystrophic epidermolysis bullosa synthesize drastically reduced amounts of collagen VII: lack of effect of transforming growth factor-beta. J Invest Dermatol 1992; 99: 808-812. (Pubitemid 23002046)
51. Lee YH, Campbell HD, Stallcup MR,. Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. Mol Cell Biol 2004; 24: 2103-2117. (Pubitemid 38248949)
52. Kawasaki H, Tsunoda K, Hata T, et al., Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 2006; 126: 2621-2630. (Pubitemid 44764046)